Home › NDC Lookup › Ingredients › Pravastatin Sodium › 55111-0231-05
Pravastatin sodium 40 mg Tablet, 500-count — NDC 55111-0231-05 package photo

Pravastatin sodium 40 mg Tablet, 500-count

by Dr.Reddy's Laboratories Limited · 500 TABLET in 1 BOTTLE (55111-231-05)
NDC 55111-0231-05
🏷️ FDA NDC (as labeled) 55111-231-05 billing pads the product segment with a zero
This package
Contains500-count Cost per ea$0.0848 NADAC Per package$42.40 / 500 tablets Pack sizes4 compare ↓
Also priced by: Medicaid pays $0.2890/unit · Part D plans $0.1412/unit — full pricing hub ↓
Also comes in: 30 tablets 55111-0231-30 90 tablets 55111-0231-90 100 tablets 55111-0231-01
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Pravastatin Sodium (different manufacturers) — 5 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Mar 13, 2025 — CGMP Deviations (Glenmark Pharmaceuticals Inc., USA) · FDA recall D-0350-2025
Class II · Mar 13, 2025 — CGMP Deviations (Glenmark Pharmaceuticals Inc., USA) · FDA recall D-0341-2025
Class II · Mar 13, 2025 — CGMP Deviations (Glenmark Pharmaceuticals Inc., USA) · FDA recall D-0349-2025
Class II · Mar 13, 2025 — CGMP Deviations (Glenmark Pharmaceuticals Inc., USA) · FDA recall D-0325-2025
Class II · Jun 28, 2024 — Failed Dissolution Specifications: results below specifications (Glenmark Pharmaceuticals Inc., USA) · FDA recall D-0612-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

🆔 Identity & classification

FDA NDC (as labeled) 55111-231-05
Product NDC 55111-231
11-digit billing NDC 55111023105
NCPDP billing unit EA — each (per item)
RxCUI 904458, 904467, 904475, 904481
UNII 3M8608UQ61
Application # ANDA076714
SPL Set ID 99cc0546-bb2d-751e-edfd-1c15a1182e0c
Established class (EPC) HMG-CoA Reductase Inhibitor
Mechanism of action Hydroxymethylglutaryl-CoA Reductase Inhibitors
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2009-12-31
Route ORAL
Dosage form TABLET
Substance PRAVASTATIN SODIUM
GPI-14 39400065100340
GPI class Pravastatin Sodium
GCN Seq No 020741
GCN 48673
HICL code 006227
Ingredient (HICL) Pravastatin Sodium
HIC1 code M
Therapeutic class — broad (HIC1) Blood
HIC2 code M4
Therapeutic class — intermediate (HIC2) Affect Blood Lipids/Sugar/Amino Acids
HIC3 code M4D
Therapeutic class — specific (HIC3) Antihyperlipidemic-Hmgcoa Reductase Inhib(Statins)
AHFS code 24:06.08.00
AHFS class Hmg-Coa Reductase Inhibitors
FDB label name PRAVASTATIN SODIUM 40 MG TAB
FDB brand name Pravastatin Sodium
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AB · RLD · RS
Why two NDCs? The FDA registers this code as 55111-231-05 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 55111-0231-05. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the HMG-CoA Reductase Inhibitor class.

Pharmacologic class HMG-CoA Reductase Inhibitor
Drug family (ATC) HMG CoA reductase inhibitors
How it works Hydroxymethylglutaryl-CoA Reductase Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerDr.Reddy's Laboratories Limited
Application holderDR REDDYS LABORATORIES INC
FDA applicationANDA076714 (ANDA)
Labeler code55111
First marketedDec 2009
Product typeHuman Prescription Drug
Portfolio148 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name PRAVASTATIN SODIUM 40 MG TAB Ingredient Pravastatin Sodium
📖 What it is MedlinePlus · NLM

Pravastatin is used to reduce the risk of heart attack and stroke decrease the amount of cholesterol (a fat-like substance that can build up and clog blood vessels causing heart attack or stroke or other health conditions) Pravastatin is in a class of medications called HMG-CoA reductase inhibitors (statins). It works by slowing how much cholesterol your body makes. This lowers the amount of cholesterol that can build up on the walls of the arteries and block blood flow to the heart, brain, and other parts of the body.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Pravastatin works in two main ways. First, it lowers your LDL (bad cholesterol) and triglycerides while nudging your HDL (good cholesterol) higher. Second — and this is the big one...
  • What exactly is pravastatin supposed to do for me?
  • Good news — pravastatin is flexible. You can take it at any time of day, morning or evening, and with or without food. The cholesterol-lowering effect is similar either way. The on...
  • Does it matter what time of day I take it, or whether I take it with food?
📖 Read our full Pravastatin guide →
1
Nutrient depletion considerations

Pravastatin Sodium may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Pravastatin Sodium nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color White
ShapeOval
ImprintRDY;274
Size18 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII M28OL1HH48
    Croscarmellose sodium is a plant-based substance derived from cellulose. It acts as a disintegrant, helping tablets and capsules break down quickly in the digestive system so the medicine can be absorbed.
  • UNII 68401960MK
    Crospovidone is a synthetic polymer made from polyvinylpyrrolidone. It acts as a disintegrant, helping tablets break apart quickly in the stomach so the medicine dissolves and absorbs into the body.
  • UNII 3NXW29V3WO
    Hypromellose is a plant-based thickener made from cellulose. It's used in medicines as a binder to hold ingredients together, a coating for tablets, and a thickener for liquids.
  • UNII EWQ57Q8I5X
    Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII 6HG8UB2MUY
    Meglumine is a sugar-alcohol compound used as a solubilizer and pH buffer in medicines. It helps dissolve drugs that don't mix well in water and maintains stable acidity levels in the formulation.
  • UNII Q662QK8M3B
    Polyethylene glycol 8000 is a synthetic polymer made from ethylene oxide. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and add bulk to the medicine.
  • UNII 7SEV7J4R1U
    A powder made from a naturally occurring mineral. In medicines, talc works as a glidant and anti-caking agent, helping tablets and capsules flow smoothly during manufacturing and preventing clumping.
  • UNII 15FIX9V2JP
    Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.

10 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.085 $42.40 / 500 tablets
Medicaid paysCMS SDUD · 12 mo $0.2890 $144.50 / 500 tablets
Medicare drug plans payPart D · Q2 2026 $0.1412 $70.60 / 500 tablets
NADAC price history (per ea) — tap or hover for the price & month
Dec 2021 Jul 2022 Dec 2025 Aug 2026 $0.091 $0.083
▼ Down 1% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Pravastatin Sodium 40 mg 16729-0010-15 Accord 90 tablets $0.083 AB FDA listed save 2%
Pravastatin Sodium 40 mg 60687-0190-01 American 100 tablets $0.085 AB Discontinued +0%
Pravastatin Sodium 40 mg 00093-7202-10 Teva 1000 tablets $0.085 AB Availability likely —
Pravastatin Sodium 40 mg 00904-5893-61 Major 100 tablets $0.085 AB Availability likely —
Pravastatin Sodium 40 mg 16714-0560-01 NorthStar 90 tablets $0.085 AB Availability likely —
Pravastatin Sodium 40 mg 50268-0667-15 AvPAK 50 tablets $0.085 AB Availability likely —
Pravastatin Sodium 40 mg 51079-0782-20 Mylan 100 tablets $0.085 AB Discontinued —
Pravastatin sodium 40 mgthis 55111-0231-05 Dr.Reddy's 500 tablets $0.085 AB Availability likely —
Pravastatin Sodium 40 mg 60687-0908-01 American 100 tablets $0.085 AB Availability likely —
Pravastatin Sodium 40 mg 68462-0197-05 Glenmark 500 tablets $0.085 AB Availability likely —
Pravastatin Sodium 40 mg 69097-0791-05 CIPLA 90 tablets $0.085 AB Availability likely —
Pravastatin Sodium 40 mg 82009-0007-10 Quallent 1000 tablets $0.085 AB Availability likely —
Pravastatin sodium 40 mg 84386-0033-90 Aurobindo 90 tablets $0.085 AB Availability likely —
Pravastatin Sodium 40 mg 68180-0487-02 Lupin 500 tablets $0.088 AB Discontinued +4%
Pravastatin Sodium 40 mg 00615-8541-05 NCS 15 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 00615-8620-05 NCS 15 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 43063-0808-30 PD-Rx 30 tablets — AB FDA listed —
Pravastatin sodium 40 mg 48433-0149-20 Safecor 100 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 50090-1533-00 A-S 30 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 50090-2024-00 A-S 30 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 50090-4206-00 A-S 30 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 50090-6826-00 A-S 90 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 50090-6911-00 A-S 90 tablets — AB FDA listed —
Pravastatin sodium 40 mg 50090-7612-00 A-S 30 tablets — AB FDA listed —
Pravastatin sodium 40 mg 50090-7613-00 A-S 90 tablets — AB FDA listed —
Pravastatin sodium 40 mg 51407-0889-10 Golden 1000 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 51655-0594-52 Northwind 30 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 51655-0708-52 Northwind 30 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 55154-5370-00 Cardinal 10 tablets — AB Discontinued —
Pravastatin Sodium 40 mg 55154-7998-00 Cardinal 10 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 55700-0994-30 Quality 30 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 60505-0170-01 Apotex 100 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 61919-0708-30 Direct_Rx 30 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 62135-0849-90 Chartwell 90 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 63629-8835-01 Bryant 90 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 63629-8910-01 Bryant 90 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 63629-8911-01 Bryant 1000 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 63629-9164-01 Bryant 30 tablets — AB FDA listed —
Pravastatin sodium 40 mg 65862-0634-05 Aurobindo 500 tablets — — FDA listed —
Pravastatin Sodium 40 mg 68071-3366-03 NuCare 30 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 68788-7009-01 Preferred 100 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 69292-0103-10 Amici 1000 tablets — AB FDA listed —
Pravastatin sodium 40 mg 70377-0047-11 Biocon 30 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 70518-0876-00 REMEDYREPACK 90 tablets — AB FDA listed —
Pravastatin sodium 40 mg 70518-4339-00 REMEDYREPACK 30 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 71205-0121-30 Proficient 30 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 71205-0294-30 Proficient 30 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 71205-0516-30 Proficient 30 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 71335-0692-01 Bryant 30 tablets — AB FDA listed —
Pravastatin sodium 40 mg 71335-2687-01 Bryant 90 tablets — AB FDA listed —
Pravastatin sodium 40 mg 71335-2746-01 Bryant 30 tablets — AB FDA listed —
Pravastatin sodium 40 mg 71335-2833-01 Bryant 90 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 71610-0879-45 Aphena 45 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 71610-0884-45 Aphena 45 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 72162-1953-00 Bryant 1000 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 72189-0061-30 DIRECT 30 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 72789-0161-30 PD-Rx 30 tablets — AB FDA listed —
Pravastatin sodium 40 mg 82868-0081-30 Northwind 30 tablets — AB FDA listed —
Pravastatin sodium 40 mg 82868-0096-30 Northwind 30 tablets — AB FDA listed —
Pravastatin Sodium 40 mg 70518-2505-00 REMEDYREPACK 30 tablets — AB Discontinued —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2009
On the market since
Dec 2009
📍
2026
Currently FDA-listed
17 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 55111-0231-05, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
30
Units reimbursed last 4 qtrs
1.5K
Gross reimbursed last 4 qtrs
$433.51
Avg / prescription
$14.45
Avg / unit
$0.2890
Latest quarter Q1 2026
19Rx
Medicaid pays / ea
$0.2890
gross reimbursed
vs
NADAC / ea
$0.0848
acquisition cost
=
Spread
+$0.2042
+241% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
100% FFS
Fee-for-service · 30 Rx Managed care · 0 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 1,500 units · 7.7 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
7.77.7
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 7.7 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
500 tablets this page55111-0231-05 30 Rx · $434
100 tablets55111-0231-01 No Medicaid data
30 tablets55111-0231-30 No Medicaid data
90 tablets55111-0231-90 No Medicaid data
Drug total (last 4 qtrs): 30 Rx · 1,500 units · $434 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Pravastatin Sodium — the program that covers self-administered drugs. 14 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Pravastatin Sodium. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$31.8M
Claims incl. refills
2.1M
Beneficiaries
1.7M
Spend / beneficiary
$18.70
Spend / claim
$15.06
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
55111-0231-01 100 TABLET in 1 BOTTLE (55111-231-01) — — 2009-12-31 Active
55111-0231-05 You're viewing this 500 TABLET in 1 BOTTLE (55111-231-05) $0.0848 / ea $42.41 2009-12-31 Active
55111-0231-30 30 TABLET in 1 BOTTLE (55111-231-30) — — 2009-12-31 Active
55111-0231-90 90 TABLET in 1 BOTTLE (55111-231-90) $0.0848 / ea $7.63 2009-12-31 Active

You're viewing the largest of 4 pack sizes for this product.

This pack has the lowest per-ea cost of the 2 priced pack sizes ($0.0848 NADAC).

Pack size FAQ

What quantity is in NDC 55111-0231-05?
NDC 55111-0231-05 is a 500-count package — 500 tablet in 1 bottle.
What is the difference between NDC 55111-0231-05 and NDC 55111-0231-30?
Both are Pravastatin sodium 40 mg Tablet — the drug itself is identical. NDC 55111-0231-05 is the 500-count package, while NDC 55111-0231-30 is the 30 tablets package.
What NDC number is used to bill for this package of Pravastatin sodium 40 mg Tablet?
Bill NDC 55111-0231-05 — the 11-digit billing format is 55111023105. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration 💊 Dosage Forms and Strengths ⛔ Contraindications ⚠️ Warnings and Cautions 🤒 Adverse Reactions 🔄 Drug Interactions 👥 Use in Specific Populations 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 🧬 Mechanism of Action 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients
🎯 Indications and Usage ~2 min read ▾

1 INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Pravastatin sodium is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI,revascularization, andcardiovascularmortalityin hypercholesterolemicpatientswithout clinicallyevidentCHD.

(1.1) Reduce the risk of total mortality by reducing coronary death, MI,revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. (1.1) Reduce elevated Total-C,LDL-C,ApoB,and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. (1.2) Reduce elevated serumTG levels in patients with hypertriglyceridemia.

(1.2) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. (1.2) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. (1.2) Limitations of use: Pravastatin sodium has not been studied in Fredrickson Types I and V dyslipidemias.

(1.3)

1.1Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablets are indicated to: reduce the risk of myocardial infarction (MI). reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. In patients with clinically evident CHD, pravastatin sodium tablets are indicated to: • reduce the risk of total mortality by reducing coronary death. • reduce the risk of MI. • reduce the risk of undergoing myocardial revascularization procedures. • reduce the risk of stroke and stroke/transient ischemic attack (TIA ). • slow the progression of coronary atherosclerosis.

1.2Hyperlipidemia Pravastatin sodium tablets are indicated:. as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia ( Fredrickson Types IIa and IIb). 1 as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV). for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III)who do not respond adequately to diet. as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: a.

LDL-C remains ≥190 mg/dL or b. LDL-C remains ≥160 mg/dL and: there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors are present in the patient.

1.3Limitations of Use Pravastatin sodium has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V).

⏱️ Dosage and Administration ~2 min read ▾

2 DOSAGE AND ADMINISTRATION Adults: the recommended starting dose is 40 mg once daily.Use 80 mg dose only for patients not reaching LDL-C goal with 40 mg. (2.2) Significant renal impairment:the recommended starting dose is pravastatin 10 mg once daily. (2.3) Children (ages 8 to 13 years,inclusive): the recommended starting dose is 20 mg once daily.( 2.4) Adolescents (ages 14 to18 years):the recommended starting dose is 40 mg once daily .(2.4 )

2.1General Dosing Information The patient should be placed on a standard cholesterol-lowering diet before receiving pravastatin sodium tablets and should continue on this diet during treatment with pravastatin sodium tablets [see NCEP Treatment Guidelines for details on dietary therapy].

2.2Adult Patients The recommended starting dose is 40 mg once daily. If a daily dose of 40 mg does not achieve desired cholesterol levels, 80 mg once daily is recommended. In patients with significant renal impairment, a starting dose of 10 mg daily is recommended.

Pravastatin sodium tablets can be administered orally as a single dose at any time of the day, with or without food. Since the maximal effect of a given dose is seen within 4 weeks, periodic lipid determinations should be performed at this time and dosage adjusted according to the patient’s response to therapy and established treatment guidelines.

2.3Patients with Renal Impairment In patients with severe renal impairment, a starting dose of 10 mg pravastatin daily is recommended. Although the pravastatin sodium 10 mg tablets are no longer available, pravastatin 10 mg tablets are available.

2.4Pediatric Patients Children (Ages 8 to 13 Years, Inclusive) The recommended dose is 20 mg once daily in children 8 to 13 years of age. Doses greater than20 mg have not been studied in this patient population. Adolescents (Ages 14 to 18 Years) The recommended starting dose is 40 mg once daily in adolescents 14 to 18 years of age.

Doses greater than 40 mg have not been studied in this patient population. Children and adolescents treated with pravastatin should be reevaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C [see Indications and Usage ( 1.2 ) ].

2.5Concomitant Lipid-Altering Therapy Pravastatin sodium tablets may be used with bile acid resins. When administering a bile-acid-binding resin (e.g., cholestyramine, colestipol) and pravastatin, pravastatin sodium tablets should be given either 1 hour or more before or at least 4 hours following the resin. [see Clinical Pharmacology ( 12.3 ). ]

2.6Dosage in Patients Taking Cyclosporine In patients taking immunosuppressive drugs such as cyclosporine concomitantly with pravastatin, therapy should begin with 10 mg of pravastatin sodium once-a-day at bedtime and titration to higher doses should be done with caution. Most patients treated with this combination received a maximum pravastatin sodium dose of 20 mg/day. In patients taking cyclosporine, therapy should be limited to 20 mg of pravastatin sodium once daily [see Warnings and Precautions ( 5.1 ) and Drug Interactions ( 7.1 ) ].

2.7Dosage in Patients Taking Clarithromycin In patients taking clarithromycin, therapy should be limited to 40 mg of pravastatin sodium once daily [see Drug Interactions ( 7.2 ) ].

💊 Dosage Forms and Strengths 95 words ▾

3 DOSAGE FORMS AND STRENGTHS Pravastatin sodium tablets USP are supplied as: 10 mg tablets: White, round, biconvex coated tablets, debossed ‘RDY’ on one side and ‘229’ on other side. 20 mg tablets: . White, round, biconvex coated tablets, debossed ‘RDY’ on one side and ‘230’ on other side.

40 mg tablets: White, round, biconvex coated tablets, debossed ‘RDY’ on one side and ‘231’ on other side. 80 mg tablets: White, oval, biconvex coated tablets, debossed ‘RDY’ on one side and ‘274’ on other side. Tablets: 10 mg, 20 mg, 40 mg, 80 mg.

(3)

⛔ Contraindications ~1 min read ▾

4 CONTRAINDICATIONS Hypersensitivity to any component of this medication.( 4.1 , 6.2 , 11 ) Active liver disease or unexplained, persistent elevations of serum transaminases.( 4.2 , 5.2 ) Women who are pegnant or may become pregnant.( 4.3 , 8.1 ) Pregnancy ( 4.3 , 8.1 , 8.3 ) Lactation ( 4.4 , 8.2 )

4.1Hypersensitivity Hypersensitivity to any component of this medication.

4.2Liver Active liver disease or unexplained, persistent elevations of serum transaminases [see Warnings and Precautions ( 5.2 ) ].

4.3Pregnancy Atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. Cholesterol and other products of cholesterol biosynthesis are essential components for fetal development (including synthesis of steroids and cell membranes). Since statins decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, they are contraindicated during pregnancy and in nursing mothers.

PRAVASTATIN SHOULD BE ADMINISTERED TO WOMEN OF CHILDBEARING AGE ONLY WHEN SUCH PATIENTS ARE HIGHLY UNLIKELY TO CONCEIVE AND HAVE BEEN INFORMED OF THE POTENTIAL HAZARDS. If the patient becomes pregnant while taking this class of drug, therapy should be discontinued immediately and the patient apprised of the potential hazard to the fetus [see Use in Specific Populations ( 8.1, 8.3 )].

4.4Lactation Pravastatin is present in human milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require pravastatin sodium treatment should not breastfeed their infants [see Use in Specific Populations ( 8.2 )].

⚠️ Warnings and Cautions ~3 min read ▾

5 WARNINGS AND PRECAUTIONS Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): predisposing factors include advanced age (≥65), uncontrolled hypothyroidism, and renal impairment. Patients should be advised to promptly report to their physician any unexplained and/or persistent muscle pain, tenderness, or weakness. Pravastatin therapy should be discontinued if myopathy is diagnosed or suspected.( 5.1 , 8.5 ) Liver enzyme abnormalities: persistent elevations in hepatic transaminases can occur.

Check liver enzyme tests before initiating therapy and as clinically indicated thereafter. ( 5.2 )

5.1Skeletal Muscle Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with pravastatin and other drugs in this class. A history of renal impairment may be a risk factor for the development of rhabdomyolysis. Such patients merit closer monitoring for skeletal muscle effects.

Uncomplicated myalgia has also been reported in pravastatin-treated patients [see Adverse Reactions (6) ]. Myopathy, defined as muscle aching or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values to greater than 10 times the ULN, was rare (<0.1%) in pravastatin clinical trials. Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation of CPK.

Predisposing factors include advanced age (≥ 65), uncontrolled hypothyroidism, and renal impairment. There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum CPK, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing myopathy without significant inflammation and improvement with immunosuppressive agents.

All patients should be advised to promptly report to their physician unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing pravastatin sodium. Pravastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. Pravastatin therapy should also be temporarily withheld in any patient experiencing an acute or serious condition predisposing to the development of renal failure secondary to rhabdomyolysis, e.g., sepsis; hypotension; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy.

The risk of myopathy during treatment with statins is increased with concurrent therapy with either erythromycin, cyclosporine, niacin, or fibrates. However, neither myopathy nor significant increases in CPK levels have been observed in 3 reports involving a total of 100 post-transplant patients (24 renal and 76 cardiac) treated for up to 2 years concurrently with pravastatin 10 to40 mg and cyclosporine. Some of these patients also received other concomitant immunosuppressive therapies.

Further, in clinical trials involving small numbers of patients who were treated concurrently with pravastatin and niacin, there were no reports of myopathy. Also, myopathy was not reported in a trial of combination pravastatin (40 mg/day) and gemfibrozil(1200 mg/day), although 4 of 75 patients on the combination showed marked CPK elevations versus 1 of 73 patients receiving placebo. There was a trend toward more frequent CPK elevations and patient withdrawals due to musculoskeletal symptoms in the group receiving combined treatment as compared with the groups receiving placebo, gemfibrozil, or pravastatin monotherapy.

The use of fibrates alone may occasionally be associated with myopathy. The benefit of further alterations in lipid levels by the combined use of pravastatin sodium with fibrates should be carefully weighed against the potential risks of this combination. Cases of myopathy, including rhabdomyolysis, have been reported with prava…

🤒 Adverse Reactions ~3 min read ▾

6 ADVERSE REACTIONS Pravastatin is generally well tolerated; adverse reactions have usually been mild and transient. In4-month-long placebo-controlled trials, 1.7% of pravastatin-treated patients and 1.2% of placebo-treated patients were discontinued from treatment because of adverse experiences attributed to study drug therapy; this difference was not statistically significant. In short-term clinical trials, the most commonly reported adverse reactions (≥2% and > placebo) regardless of causality were: musculoskeletal pain, nausea/vomiting, upper respiratory infection, diarrhea, and headache.

( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy’s Laboratories, Inc. at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1Adverse Clinical Events Short-Term Controlled Trials In the pravastatin sodium placebo-controlled clinical trials database of 1313 patients (age range 20 to 76 years, 32.4% women, 93.5% Caucasians, 5% Blacks, 0.9% Hispanics, 0.4% Asians, 0.2% Others) with a median treatment duration of 14 weeks, 3.3% of patients on pravastatin sodium and 1.2% patients on placebo discontinued due to adverse events regardless of causality. The most common adverse reactions that led to treatment discontinuation and occurred at an incidence greater than placebo were: liver function test increased, nausea, anxiety/depression, and dizziness.

All adverse clinical events (regardless of causality) reported in ≥2% of pravastatin-treated patients in placebo-controlled trials of up to 8 months duration are identified in Table 1: Table 1: Adverse Events in ³ 2% of Patients Treated with Pravastatin 5 to 40 mg and at an Incidence Greater Than Placebo in Short-Term Placebo-Controlled Trials (% of patients Body System/Event 5 mg N=100 1 0 mg N=153 2 0 mg N=478 4 0 mg N=171 Any Dose N=902 Placebo N=411 Cardiovascular Angina Pectoris 5 4.6 4.8 3.5 4.5

3.4Dermatologic Rash 3 2.6 6.7 1.2 4.5

1.4Gastrointestinal Nausea/Vomiting Diarrhea Flatulence Dyspepsia/Heartburn Abdominal Distension 4 8 2 0 2 5.9 8.5 3.3 3.3 3.3 10.5 6.5 4.6 3.6 2.1 2.3 4.7 0 0.6 0.6 7.4 6.7 3.2 2.5 2 7.1 5.6 4.4 2.7

2.4General Fatigue 4 1.3 5.2 0 3.4

3.9Chest Pain Influenza 4 4 1.3 2.6 3.3 1.9 1.2 0.6 2.7 2 1.9

0.7Musculoskeletal Musculoskeletal Pain Myalgia 13 1 3.9 2.6 13.2 2.9 5.3 1.2 10.1 2.3 10.2

1.2Nervous System Headache Dizziness 5 4 6.5 1.3 7.5 5.2 3.5 0.6 6.3 3.5 4.6

3.4Respiratory Pharyngitis Upper Respiratory Infection Rhinitis Cough 2 6 7 4 4.6 9.8 5.2 1.3 1.5 5.2 3.8 3.1 1.2 4.1 1.2 1.2 2 5.9 3.9 2.5 2.7 5.8 4.9

1.7Investigation ALT Increased g-GT Increased CPK Increased 2 3 5 2 2.6 1.3 4 2.1 5.2 1.2 0.6 2.9 2.9 2 4.1 1.2 1.2

3.6The safety and tolerability of pravastatin sodium at a dose of 80 mg in 2 controlled trials with a mean exposure of 8.6 months was similar to that of pravastatin sodium at lower doses except that 4 out of 464 patients taking 80 mg of pravastatin had a single elevation of CK >10 times ULN compared to 0 out of 115 patients taking 40 mg of pravastatin. Long-Term Controlled Morbidity and Mortality Trials In the pravastatin sodium placebo-controlled clinical trials database of 21,483 patients (age range 24 to 75 years, 10.3% women, 52.3% Caucasians, 0.8% Blacks, 0.5% Hispanics, 0.1% Asians, 0.1% Others, 46.1% Not Recorded) with a median treatment duration of 261 weeks, 8.1% of patients on pravastatin sodium and 9.3% patients on placebo discontinued due to adverse events regardless of causality.

Adverse event data were pooled from 7 double-blind, placebo-controlled trials (West of Scotland Coronary Prevention Study [WOS]; Cholesterol and Recurrent Events study [CARE]; Long-term Intervention with Pravastatin in Ischemic Disease study [LIPID]; Pravastatin Limitation of Atherosclerosis in the Coronary Arteries study [PLAC I]; Pravastatin, Lipids and Atherosclerosis in the Carotids study [PLAC II]; Regression Growth Evaluation Statin Study [REGRESS]; and Kuopio Atherosclerosis Prevention Study [KAPS]) involving…

🔄 Drug Interactions ~2 min read ▾

7 DRUG INTERACTIONS For the concurrent therapy of either cyclosporine, fibrates, niacin (nicotinic acid), or erythromycin, the risk of myopathy increases [see Warnings and Precautions ( 5.1 ) and Clinical Pharmacology ( 12.3 )]. Concomitant lipid-lowering therapies: use with fibrates or lipid-modifying doses (≥1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with pravastatin sodium.

(7) Cyclosporine:combination increases exposure. Limit pravastatin to 20 mg once daily.( 2.6 , 7.1 ) Clarithromycin: combination increases exposure. Limit pravastatin to 40 mg once daily.( 2.7 , 7.2 )

7.1Cyclosporine The risk of myopathy/rhabdomyolysis is increased with concomitant administration of cyclosporine. Limit pravastatin to 20 mg once daily for concomitant use with cyclosporine [see Dosage and Administration ( 2.6 ), Warnings and Precautions ( 5.1 ), and Clinical Pharmacology ( 12.3 )].

7.2Clarithromycin and Other Macrolide Antibiotics The risk of myopathy/rhabdomyolysis is increased with concomitant administration of clarithromycin. Limit pravastatin to 40 mg once daily for concomitant use with clarithromycin [see Dosage and Administration ( 2.7 ), Warnings and Precautions ( 5.1 ), and Clinical Pharmacology ( 12.3 )]. Other macrolides (e.g., erythromycin and azithromycin) have the potential to increase statin exposures while used in combination.

Pravastatin should be used cautiously with macrolide antibiotics due to a potential increased risk of myopathies.

7.3Colchicine The risk of myopathy/rhabdomyolysis is increased with concomitant administration of colchicine [see Warnings and Precautions (5.1) ].

7.4Gemfibrozil Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of pravastatin sodium with gemfibrozil should be avoided [see Warnings and Precautions ( 5.1) ].

7.5Other Fibrates Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, pravastatin sodium should be administered with caution when used concomitantly with other fibrates [see Warnings and Precautions (5.1 )].

7.6Niacin The risk of skeletal muscle effects may be enhanced when pravastatin is used in combination with niacin; a reduction in pravastatin sodium dosage should be considered in this setting [see Warnings and Precautions (5.1 )].

👥 Use in Specific Populations ~3 min read ▾

8 USE IN SPECIFIC POPULATIONS

8.1Pregnancy Risk Summary Pravastatin sodium is contraindicated for use in pregnant woman because of the potential for fetal harm. As safety in pregnant women has not been established and there is no apparent benefit to therapy with pravastatin sodium during pregnancy, pravastatin sodium should be immediately discontinued as soon as pregnancy is recognized [see Contraindications (4.3) ]. Limited published data on the use of pravastatin sodium in pregnant women are insufficient to determine a drug-associated risk of major congenital malformations or miscarriage.

In animal reproduction studies, no evidence of fetal malformations was seen in rabbits or rats exposed to 10 times to 120 times, respectively, the maximum recommended human dose (MRHD) of 80 mg/day. Fetal skeletal abnormalities, offspring mortality, and developmental delays occurred when pregnant rats were administered 10 times to 12 times the MRHD during organogenesis to parturition [see Data ]. Advise pregnant women of the potential risk to a fetus.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Human Data Limited published data on pravastatin have not shown an increased risk of major congenital malformations or miscarriage.

Rare reports of congenital anomalies have been received following intrauterine exposure to other statins. In a review 2 of approximately 100 prospectively followed pregnancies in women exposed to simvastatin or lovastatin, the incidences of congenital anomalies, spontaneous abortions, and fetal deaths/stillbirths did not exceed what would be expected in the general population. The number of cases is adequate to exclude a ≥3 to 4-fold increase in congenital anomalies over the background incidence.

In 89% of the prospectively followed pregnancies, drug treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. Animal Data Embryofetal and neonatal mortality was observed in rats given pravastatin during the period of organogenesis or during organogenesis continuing through weaning. In pregnant rats given oral gavage doses of 4, 20, 100, 500, and 1000 mg/kg/day from gestation days 7 through 17 (organogenesis) increased mortality of offspring and increased cervical rib skeletal anomalies were observed at ≥100 mg/kg/day systemic exposure, 10 times the human exposure at 80 mg/day MRHD based on body surface area (mg/m 2 ).

In other studies, no teratogenic effects were observed when pravastatin was dosed orally during organogenesis in rabbits (gestation days 6 through 18) up to 50 mg/kg/day or in rats (gestation days 7 through 17) up to 1000 mg/kg/day. Exposures were 10 times (rabbit) or 120 times (rat) the human exposure at 80 mg/day MRHD based on body surface area (mg/m 2 ). In pregnant rats given oral gavage doses of 10, 100, and 1000 mg/kg/day from gestation day 17 through lactation day 21 (weaning), increased mortality of offspring and developmental delays were observed at ≥100 mg/kg/day systemic exposure, corresponding to 12 times the human exposure at 80 mg/day MRHD, based on body surface area (mg/m 2 ).

In pregnant rats, pravastatin crosses the placenta and is found in fetal tissue at 30% of the maternal plasma levels following administration of a single dose of 20 mg/day orally on gestation day 18, which corresponds to exposure 2 times the MRHD of 80 mg daily based on body surface area (mg/m 2 ). In lactating rats, up to 7 times higher levels of pravastatin are present in the breast milk than in the maternal plasma, which corresponds to exposure 2 times the MRHD of 80 mg/day based on body surface area (mg/m 2 ).

8.2Lactation Risk Summary ravastatin use is contraindicated during breastfeeding [see Contrai…

🤰 Pregnancy ~3 min read ▾

8.1Pregnancy Risk Summary Pravastatin sodium is contraindicated for use in pregnant woman because of the potential for fetal harm. As safety in pregnant women has not been established and there is no apparent benefit to therapy with pravastatin sodium during pregnancy, pravastatin sodium should be immediately discontinued as soon as pregnancy is recognized [see Contraindications (4.3) ]. Limited published data on the use of pravastatin sodium in pregnant women are insufficient to determine a drug-associated risk of major congenital malformations or miscarriage.

In animal reproduction studies, no evidence of fetal malformations was seen in rabbits or rats exposed to 10 times to 120 times, respectively, the maximum recommended human dose (MRHD) of 80 mg/day. Fetal skeletal abnormalities, offspring mortality, and developmental delays occurred when pregnant rats were administered 10 times to 12 times the MRHD during organogenesis to parturition [see Data ]. Advise pregnant women of the potential risk to a fetus.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Human Data Limited published data on pravastatin have not shown an increased risk of major congenital malformations or miscarriage.

Rare reports of congenital anomalies have been received following intrauterine exposure to other statins. In a review 2 of approximately 100 prospectively followed pregnancies in women exposed to simvastatin or lovastatin, the incidences of congenital anomalies, spontaneous abortions, and fetal deaths/stillbirths did not exceed what would be expected in the general population. The number of cases is adequate to exclude a ≥3 to 4-fold increase in congenital anomalies over the background incidence.

In 89% of the prospectively followed pregnancies, drug treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. Animal Data Embryofetal and neonatal mortality was observed in rats given pravastatin during the period of organogenesis or during organogenesis continuing through weaning. In pregnant rats given oral gavage doses of 4, 20, 100, 500, and 1000 mg/kg/day from gestation days 7 through 17 (organogenesis) increased mortality of offspring and increased cervical rib skeletal anomalies were observed at ≥100 mg/kg/day systemic exposure, 10 times the human exposure at 80 mg/day MRHD based on body surface area (mg/m 2 ).

In other studies, no teratogenic effects were observed when pravastatin was dosed orally during organogenesis in rabbits (gestation days 6 through 18) up to 50 mg/kg/day or in rats (gestation days 7 through 17) up to 1000 mg/kg/day. Exposures were 10 times (rabbit) or 120 times (rat) the human exposure at 80 mg/day MRHD based on body surface area (mg/m 2 ). In pregnant rats given oral gavage doses of 10, 100, and 1000 mg/kg/day from gestation day 17 through lactation day 21 (weaning), increased mortality of offspring and developmental delays were observed at ≥100 mg/kg/day systemic exposure, corresponding to 12 times the human exposure at 80 mg/day MRHD, based on body surface area (mg/m 2 ).

In pregnant rats, pravastatin crosses the placenta and is found in fetal tissue at 30% of the maternal plasma levels following administration of a single dose of 20 mg/day orally on gestation day 18, which corresponds to exposure 2 times the MRHD of 80 mg daily based on body surface area (mg/m 2 ). In lactating rats, up to 7 times higher levels of pravastatin are present in the breast milk than in the maternal plasma, which corresponds to exposure 2 times the MRHD of 80 mg/day based on body surface area (mg/m 2 ).

🧒 Pediatric Use 137 words ▾

8.4Pediatric Use The safety and effectiveness of pravastatin sodium in children and adolescents from 8 to 18 years of age have been evaluated in a placebo-controlled study of 2 years duration. Patients treated with pravastatin had an adverse experience profile generally similar to that of patients treated with placebo with influenza and headache commonly reported in both treatment groups. [see Adverse Reactions ( 6.4 ).] Doses greater than 40 mg have not been studied in this population. Children and adolescent females of childbearing potential should be counseled on appropriate contraceptive methods while on pravastatin therapy [see Contraindications ( 4.3 ) and Use in Specific Populations ( 8.1 ) ].

For dosing information [see Dosage and Administration ( 2.4 ) .] Double-blind, placebo-controlled pravastatin studies in children less than 8 years of age have not been conducted.

🧓 Geriatric Use 197 words ▾

8.5Geriatric Use Two secondary prevention trials with pravastatin (CARE and LIPID) included a total of 6593 subjects treated with pravastatin 40 mg for periods ranging up to 6 years. Across these 2 studies, 36.1% of pravastatin subjects were aged 65 and older and 0.8% were aged 75 and older.The beneficial effect of pravastatin in elderly subjects in reducing cardiovascular events and in modifying lipid profiles was similar to that seen in younger subjects. The adverse event profile in the elderly was similar to that in the overall population.

Other reported clinical experience has not identified differences in responses to pravastatin between elderly and younger patients. Mean pravastatin AUCs are slightly (25% to 50%) higher in elderly subjects than in healthy young subjects, but mean maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax), and half-life (t½) values are similar in both age groups and substantial accumulation of pravastatin would not be expected in the elderly [see Clinical Pharmacology ( 12.3 ) ]. Since advanced age (≥65 years) is a predisposing factor for myopathy, pravastatin sodium should be prescribed with caution in the elderly [see Warnings and Precautions (5.1) and Clinical Pharmacology ( 12.3 ) ].

🆘 Overdosage 33 words ▾

10 OVERDOSAGE To date, there has been limited experience with overdosage of pravastatin. If an overdose occurs, it should be treated symptomatically with laboratory monitoring and supportive measures should be instituted as required.

🧬 Clinical Pharmacology ~3 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action Pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol. In addition, pravastatin reduces VLDL and TG and increases HDL-C.

12.3Pharmacodynamics General Absorption: Pravastatin sodium is administered orally in the active form. In studies in man, peak plasma pravastatin concentrations occurred 1 to 1.5 hours upon oral administration. Based on urinary recovery of total radiolabeled drug, the average oral absorption of pravastatin is 34% and absolute bioavailability is 17%.

While the presence of food in the gastrointestinal tract reduces systemic bioavailability, the lipid-lowering effects of the drug are similar whether taken with or1 hour prior to meals. Pravastatin plasma concentrations, including area under the concentration-time curve (AUC), Cmax, and steady-state minimum (Cmin), are directly proportional to administered dose. Systemic bioavailability of pravastatin administered following a bedtime dose was decreased 60% compared to that following an AM dose.

Despite this decrease in systemic bioavailability, the efficacy of pravastatin administered once daily in the evening, although not statistically significant, was marginally more effective than that after a morning dose. The coefficient of variation (CV), based on between-subject variability, was 50% to 60% for AUC. The geometric means of pravastatin Cmax and AUC following a 20 mg dose in the fasted state were 26.5 ng/mL and 59.8 ng*hr/mL, respectively.

Steady-state AUCs, Cmax, and Cmin plasma concentrations showed no evidence of pravastatin accumulation following once or twice daily administration of pravastatin sodium tablets. Distribution: Approximately 50% of the circulating drug is bound to plasma proteins. Metabolism: The major biotransformation pathways for pravastatin are: (a) isomerization to 6­ epi pravastatin and the 3α-hydroxyisomer of pravastatin (SQ 31,906) and (b) enzymatic ring hydroxylation to SQ 31,945.

The 3α-hydroxyisomeric metabolite (SQ 31,906) has 1/10 to 1/40 the HMG-CoA reductase inhibitory activity of the parent compound. Pravastatin undergoes extensive first-pass extraction in the liver (extraction ratio 0.66). Excretion: Approximately 20% of a radiolabeled oral dose is excreted in urine and 70% in the feces.

After intravenous administration of radiolabeled pravastatin to normal volunteers, approximately 47% of total body clearance was via renal excretion and 53% by non-renal routes (i.e., biliary excretion and biotransformation). Following single dose oral administration of 14 C-pravastatin, the radioactive elimination t½ for pravastatin is 1.8 hours in humans. Specific Populations Renal Impairment: A single 20 mg oral dose of pravastatin was administered to 24 patients with varying degrees of renal impairment (as determined by creatinine clearance).

No effect was observed on the pharmacokinetics of pravastatin or its 3α-hydroxy isomeric metabolite (SQ 31,906). Compared to healthy subjects with normal renal function, patients with severe renal impairment had 69% and 37% higher mean AUC and Cmax values, respectively, and a 0.61 hour shorter t½ for the inactive enzymatic ring hydroxylation metabolite (SQ 31,945). Hepatic Impairment: In a study comparing the kinetics of pravastatin in patients with biopsy confirmed cirrhosis (N=7) and normal subjects (N=7), the mean AUC varied 18-fold in cirrhotic patients and 5-fold in healthy subjects.

Similarly, the peak pravastatin values varied 47-fold for cirrhotic patients compared to 6-fold for healthy subjects. [see Warnings and Precautions ( 5.2 ) .] Geriatric: In a single oral dose study using pravastatin 20 mg, the mean AUC for pravastatin was approximately 27% greater and the mean cumulative urinary excretion (CUE) approximately 19% lower in elderly men (65 to 75 yea…

🧬 Mechanism of Action 46 words ▾

12.1Mechanism of Action Pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol. In addition, pravastatin reduces VLDL and TG and increases HDL-C.

📦 How Supplied / Storage and Handling ~1 min read ▾

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1How Supplied Pravastatin sodium tablets USP are supplied as: 10 mg tablets: White, round, biconvex coated tablets, debossed ‘RDY’ on one side and ‘229’ on other side and are supplied in bottles of 30, 90, 100 and 500. Bottles of 30 NDC 55111-229-30 Bottles of 90 NDC 55111-229-90 Bottles of 100 NDC 55111-229-01 Bottles of 500 NDC 55111-229-05 20 mg tablets: White, round, biconvex coated tablets, debossed ‘RDY’ on one side and ‘230’ on other side and are supplied in bottles of 30, 90, 100 and 500. Bottles of 30 NDC 55111-230-30 Bottles of 90 NDC 55111-230-90 Bottles of 100 NDC 55111-230-01 Bottles of 500 NDC 55111-230-05 40 mg tablets: White, round, biconvex coated tablets, debossed ‘RDY’ on one side and ‘231’ on other side and are supplied in bottles of 30, 90, 100 and 500.

Bottles of 30 NDC 55111-231-30 Bottles of 90 NDC 55111-231-90 Bottles of 100 NDC 55111-231-01 Bottles of 500 NDC 55111-231-05 80 mg tablets: White, oval, biconvex coated tablets, debossed ‘RDY’ on one side and ‘274’ on other side and are supplied in bottles of 30, 90, 100 and 500. Bottles of 30 NDC 55111-274-30 Bottles of 90 NDC 55111-274-90 Bottles of 100 NDC 55111-274-01 Bottles of 500 NDC 55111-274-05

16.2Storage Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Keep tightly closed (protect from moisture). Protect from light.

📋 Description 162 words ▾

11 DESCRIPTION Pravastatin sodium USP is one of a class of lipid-lowering compounds, the statins, which reduce cholesterol biosynthesis. These agents are competitive inhibitors of HMG-CoA reductase, the enzyme catalyzing the early rate-limiting step in cholesterol biosynthesis, conversion of HMG-CoA to mevalonate. Pravastatin sodium USP is designated chemically as 1-Naphthalene-heptanoic acid, 1,2,6,7,8,8a­hexahydro-β,δ,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-,monosodium salt,[1S­ [1α(βS*,δS*),2α,6α,8β(R*),8aα]]-.

Structural formula: Pravastatin sodium USP is an white to yellowish white, hygroscopic powder. It is a relatively polar hydrophilic compound with a partition coefficient (octanol/water) of 0.59 at a pH of 7.0. It is freely soluble in water, in methanol, soluble in alcohol, very slightly soluble in acetonitrile, practically insoluble in ether, in ethyl acetate, and in chloroform.

Pravastatin sodium tablets USP are available for oral administration as 10 mg, 20 mg, 40 mg or 80 mg tablets. Inactive ingredients include: croscarmellose sodium, crospovidone, magnesium stearate, meglumine, microcelac 100 (lactose monohydrate and microcrystalline cellulose), microcrystalline cellulose, opadry white YS-1-7040 (hypromellose 2910, polyethylene glycol 8000, talc, and titanium dioxide).

💬 Information for Patients 195 words ▾

17 PATIENT COUNSELING INFORMATION Muscle Pain Patients should be advised to report promptly unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever or if these muscle signs or symptoms persist after discontinuing pravastatin [see Warnings and Precautions ( 5.1 ) ]. Liver Enzymes It is recommended that liver enzyme tests be performed before the initiation of pravastatin sodium, and thereafter when clinically indicated. All patients treated with pravastatin sodium should be advised to promptly report any symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice [see Warnings and Precautions ( 5.2 )].

Embryofetal Toxicity Advise females of reproductive potential of the risk to a fetus, to use effective contraception during treatment, and to inform their healthcare provider of a known or suspected pregnancy [see Contraindications (4.3 ), Use in Specific Populations ( 8.1 , 8.3 )]. Lactation Advise women not to breastfeed during treatment with pravastatin sodium[see Contraindications ( 4.4 ), Use in Specific Populations ( 8.2 )]. Rx Only Manufactured by: Dr.

Reddy’s Laboratories Limited Bachupally - 500 090 INDIA Distributed by: Dr. Reddy’s Laboratories Inc., Princeton, NJ 08540 USA Revised: 0118

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 55111-0230-01 · Dr.Reddy's 55111-0248-01 · Dr. →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.